Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study

  • S. Deshayes
  • E. Liozon
  • N. Chanson
  • K. Sacré
  • T. Moulinet
  • C. Blanchard-Delaunay
  • O. Espitia
  • M. Groh
  • M. Versini
  • T. Le Gallou
  • J.-E. Kahn
  • V. Grobost
  • S. Humbert
  • M. Samson
  • R. Mourot Cottet
  • K. Mazodier
  • A. Dartevel
  • J. Campagne
  • A. Dumont
  • B. Bienvenu
  • M. Lambert
  • A. Daumas
  • D. Saadoun
  • A. Aouba
  • H. de BoyssonEmail author
  • on behalf of the French Study Group for Large Vessel Vasculitis (GEFA)
Original Article
Part of the following topical collections:
  1. Autoimmune Collection 2018



Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group.


Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients.


Forty-nine observations were collected (median age 76 years). Malignancies comprised 33 (67%) solid neoplasms and 16 (33%) clonal hematologic disorders. No over-representation of a particular type of malignancy was observed. Diagnosis of GCA and malignancy was synchronous in 7 (14%) patients, while malignancy succeeded GCA in 29 (59%) patients. Malignancy was fortuitously diagnosed based on abnormalities observed in laboratory tests in 26 patients, based on imaging in 14 patients, and based on symptoms or clinical examination in the nine remaining patients. Two patients had a concomitant relapse of both conditions. When compared to the control group, patients with concomitant GCA and malignancy were more frequently male (p < 0.001), with an altered general state (p < 0.001), and polymyalgia rheumatica (p < 0.01).


This study does not indicate an over-representation of any particular type of malignancy in GCA patients. Initial follow-up dictated by vasculitis may have led to an early identification of malignancy. Nevertheless, GCA male patients with an altered general state and polymyalgia rheumatica might more frequently show concomitant malignancies.


Giant cell arteritis Hematologic neoplasms Malignancy Neoplasms 


Compliance with ethical standards

Ethical standards

This study was conducted in compliance with good clinical practices and the Declaration of Helsinki principles. At the time of this study, in accordance with French public health law (Art. L 1121-1-1, Art. L 1121-1-2), formal approval from an ethics committee was not required for this type of observational study. Our local ethics committee confirmed the observational non-interventional retrospective nature of our cohort.

Conflicts of interest

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Maxime Samson declares invitations to congresses by Abbvie, Roche Chugaï, Actelion, Novartis and LFB; symposium for Roche Chugaï and belongs to scientific committee of Roche Chugaï. The other authors declare that they have no relevant financial interests.


  1. 1.
    Weyand CM, Goronzy JJ (2014) Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371:50–57CrossRefGoogle Scholar
  2. 2.
    Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442CrossRefGoogle Scholar
  3. 3.
    Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B (2017) Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 16:833–844CrossRefGoogle Scholar
  4. 4.
    Ramadan SM, Fouad TM, Summa V, Hasan SK, Lo-Coco F (2012) Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 97:805–817CrossRefGoogle Scholar
  5. 5.
    Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR (2010) Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 95:1216–1220CrossRefGoogle Scholar
  6. 6.
    Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, ParIès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57:1473–1480Google Scholar
  7. 7.
    Agha A, Bateman H, Sterrett A, Valeriano-Marcet J (2012) Myelodysplasia and malignancy-associated vasculitis. Curr Rheumatol Rep 14:526–531CrossRefGoogle Scholar
  8. 8.
    Hutson TE, Hoffman GS (2000) Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res 13:417–423CrossRefGoogle Scholar
  9. 9.
    Kurzrock R, Cohen PR (1993) Vasculitis and cancer. Clin Dermatol 11:175–187CrossRefGoogle Scholar
  10. 10.
    Solans-Laque R, Bosch-Gil JA, Pérez-Bocanegra C et al (2008) Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 35:294–304Google Scholar
  11. 11.
    Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S, Guaschino G, Bonometti R, Pedrazzoli R, Pirisi M, Sainaghi PP (2017) Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med 12:621–627CrossRefGoogle Scholar
  12. 12.
    Galland J, Kawski H, Guichard J-F, Maurier F (2017) Vascularite des gros vaisseaux et syndrome myélodysplasique : une association rare. Rev Med Interne 38:474–477CrossRefGoogle Scholar
  13. 13.
    Yu K-H, Kuo C-F, Huang LH, Huang WK, See LC (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore) 95:e3540CrossRefGoogle Scholar
  14. 14.
    Zurada JM, Ward KM, Grossman ME (2006) Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol 55:S65–S70CrossRefGoogle Scholar
  15. 15.
    Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) 39:417–420CrossRefGoogle Scholar
  16. 16.
    Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91:403–408CrossRefGoogle Scholar
  17. 17.
    Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology 43:626–632Google Scholar
  18. 18.
    de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 63:1188–1194CrossRefGoogle Scholar
  19. 19.
    Berthier S, Magy N, Gil H, Becker Schneider M, Vuitton DA, Dupond JL (2001) Myélodysplasies et maladies systémiques. Une association non fortuite. Rev Med Interne 22:428–432CrossRefGoogle Scholar
  20. 20.
    Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, Ronco P, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O, on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON) (2018) Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk Lymphoma 59:1399–1405CrossRefGoogle Scholar
  21. 21.
    Billström R, Johansson H, Johansson B, Mitelman F (1995) Immune-mediated complications in patients with myelodysplastic syndromes–clinical and cytogenetic features. Eur J Haematol 55:42–48CrossRefGoogle Scholar
  22. 22.
    Ustwani OA, Ford LA, Sait SJN, Block AMW, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Ambrus J Jr, Wetzler M (2013) Myelodysplastic syndromes and autoimmune diseases—case series and review of literature. Leuk Res 37:894–899CrossRefGoogle Scholar
  23. 23.
    Liozon E, Loustaud-Ratti V, Soria P, Bezanahary H, Fauchais AL, Nadalon S, Rhaiem K, Ly K, Vidal É (2004) Disease associations in 250 patients with temporal (giant cell) arteritis. Presse Med 33:1304–1312CrossRefGoogle Scholar
  24. 24.
    Liozon E, Loustaud V, Fauchais A-L, Soria P, Ly K, Ouattara B, Rhaiem K, Nadalon S, Vidal E (2006) Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol 33:1606–1614Google Scholar
  25. 25.
    Mertens JCC, Willemsen G, Van Saase J et al (1995) Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol 14:650–655CrossRefGoogle Scholar
  26. 26.
    Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, Peña-Sagredo JL, Lopez-Agreda H, Miranda-Filloy JA, Gonzalez-Juanatey C, Sanchez-Andrade A, Martin J, Llorca J (2007) Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum 37:156–163CrossRefGoogle Scholar
  27. 27.
    Hill CL, Cole A, Rischmueller M, Dodd T, Coleman M, Tucker G, Roberts-Thomson P (2010) Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology 49:756–759CrossRefGoogle Scholar
  28. 28.
    Kermani TA, Schäfer VS, Crowson CS et al (2010) Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res (Hoboken) 62:149–154CrossRefGoogle Scholar
  29. 29.
    Ninan J, Nguyen A-M, Cole A et al (2011) Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol 38:2215–2217CrossRefGoogle Scholar
  30. 30.
    Lee YH, Song GG (2018) Overall and cause-specific mortality in giant cell arteritis: a meta-analysis. Z Rheumatol 77:946–951. CrossRefGoogle Scholar
  31. 31.
    Bengtsson B, Malmvall B-E (1981) Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 209:337–345CrossRefGoogle Scholar
  32. 32.
    von Knorring J, Somer T (1974) Malignancy in association with polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol 3:129–135CrossRefGoogle Scholar
  33. 33.
    Andersson R, Malmvall B-E, Bengtsson B (1986) Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 220:465–469CrossRefGoogle Scholar
  34. 34.
    Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K (2010) Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 49:1158–1163CrossRefGoogle Scholar
  35. 35.
    Ješe R, Rotar Ž, Tomšič M, Hočevar A (2018) Giant cell arteritis and malignancy-more than just a coincidence? J Clin Rheumatol 24:85–86. CrossRefGoogle Scholar
  36. 36.
    Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT (2002) No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 29:2143–2147Google Scholar
  37. 37.
    Ungprasert P, Sanguankeo A, Upala S, Knight EL (2014) Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum 44:366–370CrossRefGoogle Scholar
  38. 38.
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128CrossRefGoogle Scholar
  39. 39.
    Institut national du cancer (2018) Les cancers en France, édition 2017Google Scholar
  40. 40.
    Park HJ, Ranganathan P (2011) Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin N Am 37:593–606CrossRefGoogle Scholar
  41. 41.
    Baslund B, Helleberg M, Faurschou M, Obel N (2015) Mortality in patients with giant cell arteritis. Rheumatology (Oxford) 54:139–143CrossRefGoogle Scholar
  42. 42.
    Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, Rey G, Mahr A (2018) Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford) 57:1047–1055CrossRefGoogle Scholar
  43. 43.
    Hamidou MA, El Kouri D, Audrain M, Grolleau JY (2001) Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann Rheum Dis 60:293–295CrossRefGoogle Scholar
  44. 44.
    Podjasek JO, Wetter DA, Pittelkow MR, Wada DA (2012) Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 66:e55–e65CrossRefGoogle Scholar
  45. 45.
    Wolach O, Stone R (2016) Autoimmunity and inflammation in myelodysplastic syndromes. Acta Haematol 136:108–117CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • S. Deshayes
    • 1
  • E. Liozon
    • 2
  • N. Chanson
    • 3
  • K. Sacré
    • 3
  • T. Moulinet
    • 4
  • C. Blanchard-Delaunay
    • 5
  • O. Espitia
    • 6
  • M. Groh
    • 7
  • M. Versini
    • 8
  • T. Le Gallou
    • 9
  • J.-E. Kahn
    • 10
  • V. Grobost
    • 11
  • S. Humbert
    • 12
  • M. Samson
    • 13
  • R. Mourot Cottet
    • 14
  • K. Mazodier
    • 15
  • A. Dartevel
    • 16
  • J. Campagne
    • 17
  • A. Dumont
    • 1
  • B. Bienvenu
    • 18
  • M. Lambert
    • 19
  • A. Daumas
    • 20
  • D. Saadoun
    • 21
  • A. Aouba
    • 1
  • H. de Boysson
    • 1
    Email author
  • on behalf of the French Study Group for Large Vessel Vasculitis (GEFA)
  1. 1.Department of Internal Medicine and Clinical ImmunologyNormandie Univ, UNICAEN, CHU de Caen NormandieCaenFrance
  2. 2.Department of Internal MedicineCHU LimogesLimogesFrance
  3. 3.Department of Internal MedicineHôpital BichatParisFrance
  4. 4.Department of Internal MedicineHôpitaux Privés de MetzMetzFrance
  5. 5.Department of Internal MedicineCentre Hospitalier Georges RenonNiortFrance
  6. 6.Department of Internal MedicineCHU NantesNantesFrance
  7. 7.Department of Internal Medicine, National Referral Center for Hypereosinophilic Syndromes (CEREO)Hôpital FochSuresnesFrance
  8. 8.Institut Arnault TzanckSaint Laurent du VarFrance
  9. 9.Department of Internal MedicineCHU RennesRennesFrance
  10. 10.Department of Internal MedicineHôpital Ambroise ParéBoulogne BillancourtFrance
  11. 11.Department of Internal MedicineCHU EstaingClermont-FerrandFrance
  12. 12.Department of Internal MedicineCHU de BesançonBesançonFrance
  13. 13.Department of Internal Medicine and Clinical ImmunologyCHU DijonDijonFrance
  14. 14.Department of Internal MedicineHôpital CivilStrasbourgFrance
  15. 15.Department of Internal MedicineHôpital de la ConceptionMarseilleFrance
  16. 16.Department of Internal MedicineCHU GrenobleGrenobleFrance
  17. 17.Department of Infectious and Systemic DiseasesHôpital d’Instruction des ArméesMetzFrance
  18. 18.Department of Internal MedicineHôpital Saint JosephMarseilleFrance
  19. 19.Department of Internal MedicineCHU de LilleLilleFrance
  20. 20.Department of Geriatric and Internal MedicineCHU de MarseilleMarseilleFrance
  21. 21.Department of Internal MedicineHôpital Pitié SalpétrièreParisFrance

Personalised recommendations